Speclipse, Inc

Speclipse, Inc., is the medical device developer of the worlds first cancer diagnostic solution based on laser-induced plasma spectroscopy (LIPS) and artificial intelligence (AI) technology. Our core technology, Spectra-Scope, embodies a real-time, non-invasive, in-vivo diagnosis of skin cancers without compromising efficacy and accuracy while preventing unnecessary biopsies. We are committed to providing innovative medical technology to assist in challenging diagnosis casesand it is our mission to continue to improve our technology so physicians can spend more time focusing on their patients and making accurate diagnoses

Skin cancer awareness,skin cancer prevention,skin cancer screening,dermatology,laser treatment,laser-induced plasma spectroscopy,artificial intelligence,medical technology,medical device development,and cancer diagnostic technology

Speclipse, inc operates in the Medical device industry.

Speclipse, inc's revenue is 11m - 100m

Speclipse, inc has 11 - 50 employees.